Credit Acceptance (CACC) posted strong fourth-quarter results, surpassing revenue and profit forecasts. The auto finance firm credits its performance to new digital tools for dealers and strategic investments in AI, aiming to deepen partnerships in a competitive market.
Dolby Laboratories surpassed Wall Street's Q4 revenue and profit forecasts, fueled by strong growth in automotive partnerships and streaming adoption. However, a year-over-year sales decline and contracting operating margins highlight the challenges of shifting product mix and restructuring costs.
Uber's strategic investment in self-driving startup Waabi, founded by its former AI chief, signals a major push into robotaxis. The $1 billion deal underscores Uber's sprawling portfolio of over 20 AV partnerships, raising questions about its 'bet-on-everything' approach in the high-stakes race for autonomy.
From innovative financing for indie labels to major acquisitions in live events, the music business landscape is being reshaped by a series of strategic partnerships and investments unveiled over the past fortnight.
Rogers Communications Inc. reported robust fourth-quarter 2025 results, with revenue reaching C$6.17 billion and net income of C$743 million. The company's strategic pivot into sports and media, fueled by the MLSE acquisition and content partnerships, is emerging as a significant growth driver, challenging its traditional telecom narrative.
CNBC's Jim Cramer offers a detailed take on NVIDIA's stock trajectory, highlighting analyst optimism around its data center partnerships while expressing skepticism over reported Chinese AI chip purchases.
The long-term strategic partnership will leverage IQVIA's data-as-a-service platform to unify and streamline commercial data across 59 countries, aiming to accelerate product launches and enhance decision-making for the pharmaceutical giant.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
The protective packaging leader's 2025 recycling achievement, driven by customer partnerships and its EmeraldPak product, marks a significant step in its 'Stairway to Green' initiative and underscores growing industry momentum for closed-loop systems.
As data center demand surges, NextEra Energy emerges as a critical, and often overlooked, infrastructure player. Its partnerships with tech titans like Meta and Google highlight a strategic pivot in the energy sector.
Microsoft posts record cloud and AI-driven revenue for Q2, fueled by new partnerships and its custom AI chip. However, a significant surge in capital expenditures for AI infrastructure and a slight deceleration in Azure growth triggered the stock's worst single-day drop since 2020, testing investor resolve on the long-term payoff.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
Dolby Laboratories (NYSE: DLB) kicked off fiscal 2026 with robust first-quarter results, exceeding its own revenue and earnings forecasts. The audio-visual technology leader credits strong deal timing and highlighted significant momentum in automotive, television, and mobile partnerships, including expanded ties with Qualcomm and major social media platforms.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
H.C. Wainwright and Chardan Capital upgrade Korro Bio (KRRO) to Buy, citing the independent potential of its RNA-editing asset KRRO-121 and strong preclinical data as key catalysts.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
